The rule every foreign device manufacturer must know before shipping to a US clinical site
Under 21 CFR 812.18(a), a company located outside the United States cannot itself serve as the sponsor of an FDA Investigational Device Exemption study. A US person, meaning an individual or legal entity with a physical presence inside the United States, must step into the sponsor role and carry every obligation listed in 21 CFR Part 812. This is not a technicality that can be addressed after device shipment. It is a structural requirement that must be resolved before the first unit of your investigational device crosses the US border.
What actually triggers the 812.18(a) sponsor requirement
Shipping an investigational device into the United States for use in a clinical study is the specific act that triggers the 812.18(a) sponsor requirement. This trigger is independent of your US importer of record designation under Customs and Border Protection rules, and it is separate from any FDA US Agent appointment you may have made under 21 CFR 807.40. Those roles carry their own obligations but they do not satisfy the IDE sponsor requirement. The moment your device enters the country for investigational use, FDA expects a US sponsor to already be identified, documented in your IDE application, and actively managing sponsor responsibilities.
The regulation states: 'If a sponsor is located outside the United States, the sponsor shall designate a United States agent as its sponsor.' See 21 CFR 812.18(a) on eCFR. Reading that sentence carefully, the designated US agent under 812.18 assumes full sponsor obligations, not merely a communication relay function. FDA will look to that US person, not the foreign manufacturer, when reviewing IDE submissions, responding to deficiency letters, or initiating an inspection.
Three structures a foreign manufacturer can use to fill the sponsor role
Foreign manufacturers typically choose among three structural approaches when addressing the 812.18(a) requirement. Each carries different cost and timeline implications, and the right choice depends on your corporate structure, study timeline, and long-term US commercialization strategy.
- A US subsidiary: Establishing or designating an existing US subsidiary as the IDE sponsor gives the foreign parent entity direct corporate control over the study, but it requires that the subsidiary have the internal regulatory infrastructure to manage Part 812 obligations, which can take six to eighteen months and meaningful operational investment to build correctly.
- A US physician acting as sponsor investigator: A qualified US physician at the clinical site can serve as both sponsor and investigator under 21 CFR 812.3(o), absorbing both roles simultaneously; this path is most practical for small feasibility studies under a nonsignificant risk device determination, though it places significant regulatory burden on a clinician who may not have dedicated regulatory staff.
- A contracted US sponsor of record: Engaging a specialized US regulatory firm to serve as the contractual sponsor of record typically delivers the fastest path to IDE readiness, often within two to six weeks, because the sponsor of record infrastructure already exists and Part 812 obligations are managed by professionals who do this full time.
You can review a detailed comparison of these three paths using the ADB US Sponsor Decision Tool, which walks through the key decision variables for your specific situation.
What the US sponsor actually owns once the IDE is active
Whoever accepts the sponsor role under 812.18(a) owns the full scope of Part 812 obligations. That includes preparing and submitting the IDE application, maintaining all required records, submitting annual progress reports and unanticipated adverse device effect reports, overseeing investigator selection and training, monitoring the investigation, and managing any IDE amendments. The ADB US Sponsor Obligations Checklist provides a structured review of every Part 812 requirement so that no obligation is overlooked before your study goes active.
FDA has issued warning letters and placed clinical holds on studies where the sponsor of record could not demonstrate actual control over these functions. Naming a US sponsor on paper while the foreign manufacturer runs the study operationally is not a compliant arrangement. The designated US sponsor must be in a position to respond to FDA correspondence, produce records on request, and make real-time decisions about the investigation.
Assessing your current structure before you ship
If your device is approaching US clinical site activation and your 812.18(a) sponsor structure has not been formally reviewed, now is the time to assess that gap. The regulatory consequences of shipping without a compliant US sponsor in place range from IDE deficiency notices to shipment holds, and correcting the structure mid-study is far more disruptive than addressing it in advance.
ADB Consulting and CRO Inc. serves as a contracted US Sponsor of Record for non US medical device companies conducting FDA-regulated clinical investigations, providing full Part 812 sponsor representation so that your study launches on a compliant foundation. Learn more about how the model works at adbccro.com/us-sponsor.
Reviewed October 28, 2026 by ADB's regulatory team.
Frequently asked questions
Does my FDA US Agent appointment under 21 CFR 807.40 satisfy the 812.18(a) sponsor requirement?
No. A US Agent appointed under 21 CFR 807.40 serves a specific communication function related to device establishment registration and is not the same as the US sponsor designation required under 21 CFR 812.18(a). The two roles are legally distinct. Your US Agent may have no awareness of your IDE obligations and no authority to act on your behalf in the context of a clinical investigation. A separate 812.18(a) sponsor structure must be in place before investigational device shipment to a US clinical site.
Can the foreign manufacturer remain involved operationally if a US sponsor of record is contracted?
Yes, and in most cases the foreign manufacturer remains the primary driver of clinical and technical decisions. The contracted US sponsor of record assumes the regulatory and administrative obligations that FDA requires a US person to own, while the foreign manufacturer continues to provide device expertise, clinical data review, and strategic direction. The arrangement should be documented in a written agreement that clearly delineates responsibilities so that both parties and FDA can see exactly who owns each Part 812 function.
What happens if a nonsignificant risk device study begins at a US site without a compliant 812.18(a) sponsor structure?
A nonsignificant risk device study conducted under an Institutional Review Board abbreviated IDE process still requires a US sponsor under 812.18(a) if the sponsor is located outside the United States. Conducting the study without that structure in place exposes the investigation to FDA enforcement action, potential IRB withdrawal of approval, and data integrity questions that could affect a future 510(k) or De Novo submission relying on that clinical evidence. ADB recommends assessing your sponsor structure before IRB submission, not after, so that any structural gaps are resolved before they affect your regulatory timeline.
Ready to assess your 812.18(a) sponsor structure before your device ships? Book a free discovery call with ADB's regulatory team at adbccro.com and we will review your current situation and outline a path forward tailored to your study design and timeline.
Related reading: our US Sponsor of Record program covers this in more depth.
Ready to Navigate the FDA Process with Confidence?
Book a free 30-minute discovery call with ADB's regulatory team to discuss your specific device and situation.
Book a Free Pathway Call